000 01492 a2200385 4500
005 20250518083130.0
264 0 _c20201030
008 202010s 0 0 eng d
022 _a1699-3055
024 7 _a10.1007/s12094-020-02302-0
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSantaballa, A
245 0 0 _aSEOM clinical guideline for secondary prevention (2019).
_h[electronic resource]
260 _bClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
_cFeb 2020
300 _a187-192 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aClinical Trials as Topic
_xstandards
650 0 4 _aHumans
650 0 4 _aMedical Oncology
650 0 4 _aNeoplasms
_xtherapy
650 0 4 _aPractice Guidelines as Topic
_xstandards
650 0 4 _aSecondary Prevention
_xmethods
650 0 4 _aSocieties, Medical
700 1 _aPinto, Á
700 1 _aBalanyà, R P
700 1 _aRamírez Merino, N
700 1 _aMartín, I R
700 1 _aGrau, S S
700 1 _aFombella, J P B
700 1 _aCano, J M
700 1 _aGonzález, C H
700 1 _aBayo, J
773 0 _tClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
_gvol. 22
_gno. 2
_gp. 187-192
856 4 0 _uhttps://doi.org/10.1007/s12094-020-02302-0
_zAvailable from publisher's website
999 _c30584308
_d30584308